A randomized trial shows that andexanet can stem the progression of intracranial hemorrhage better than 4-factor prothrombin complex concentrate in patients taking factor Xa inhibitors. The clinical relevance is unclear, though, as patient-centered outcomes were not improved, and andexanet resulted in more serious thrombotic events than PCC.
Factor Xa in…